Statement from NIH Director Jay Bhattacharya and NIAID Acting Director John H. Powers III on the New NIH Vaccinology and Immunology Center National Institutes of Health (NIH) | (.gov)
Rapid boosting increases germinal center responses to sequential vaccines Nature
Chris Boshoff։ Pfizer Highlights Q3 R&D Progress Across Oncology, Internal Medicine, Vaccines, and Immunology Oncodaily
Covid-19 Vaccines — Immunity, Variants, Boosters NEJM
Technological breakthroughs and advancements in the application of mRNA vaccines: a comprehensive exploration and future prospects Frontiers
Linking vaccine adjuvant mechanisms of action to function Science | AAAS
A guide to vaccinology: from basic principles to new developments Nature
Long-term immunity following yellow fever vaccination: a systematic review and meta-analysis The Lancet
COVID-19 immunity: Infection compared with vaccination British Society for Immunology
Editorial: Beyond Th1: Novel concepts in tuberculosis vaccine immunology Frontiers
Is this proposition a $4 billion giveaway to a billionaire’s LA research center? CalMatters
FDA approves first ever plasmid DNA-based immunotherapy Drug Discovery News
What to watch this respiratory season, from H1N1 to mRNA vaccines Chief Healthcare Executive
Cancer vaccines as enablers of immunotherapy Nature
COVID-19 Vaccines Trigger Distinct Respiratory Immune Responses in Ugandan Adults Bioengineer.org
Laboratory of Malaria Immunology and Vaccinology National Institute of Allergy and Infectious Diseases (NIAID) (.gov)
Immune response after COVID-19 vaccination British Society for Immunology
Eliciting antitumor immunity via therapeutic cancer vaccines Nature
Immunological factors linked to geographical variation in vaccine responses Nature
Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine Nature
Newly discovered immune cells in chickens could lead to more effective poultry vaccines All about feed
No Evidence Links Adenovirus Infection to Vaccine-Induced Clotting Bioengineer.org
From Vaccines to Cancer Therapies: Transforming the Future of Medicine with the Endless Potential of mRNA GeneOnline
Health Canada approves Moderna's mRNA flu and flu-COVID combo vaccines Kelowna Courier
In a melanoma trial, 89% of targets in a personalized cancer vaccine triggered an immune response. Stock Titan
Major update on future of historic Gloucestershire site at risk gazetteseries.co.uk
Centuries-old Gloucestershire hut where history was made is now saved Gloucestershire Live
Pfizer stock gains as new products lift 2026 outlook ad-hoc-news.de
AI Cancer Vaccine Achieves 75% Melanoma Response and 3-Year Remission: Evaxion Data at SITC 2026 Tech Times
Evaxion Files Registration Statement Amendment Related to EIB Debt Settlement TipRanks